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Background:  Coronary  risk  factors  for the  onset  of acute  coronary  syndrome  (ACS), including  polyunsat-
urated  fatty  acids  (PUFAs),  in younger  adult  patients  may  be different  from  those  in  older  patients.
Methods and  results:  We  enrolled  578  patients  who  underwent  coronary  angiography  at Fukuoka  Saiseikai
Hospital,  and  divided  them  into  a younger  adult group  (YG)  (<50  years,  n  =  47)  and a  middle-aged  older
group  (OG) (≥50  years,  n = 531).  In a multivariate  analysis,  lower  levels  of  high-density  lipoprotein  choles-
terol  and  the  ratio  of  eicosapentaenoic  acid  (EPA)  to arachidonic  acid (AA)  (EPA/AA),  and less aspirin,  oral
hypoglycemic  agent,  and  calcium  channel  blocker  (CCB)  use  were  independent  risk  factors  for ACS  in all
patients.  In YG, lower  levels  of EPA/AA  and less  angiotensin  II receptor  blocker/angiotensin-converting
enzyme  inhibitor  use  were  the  independent  risk  factors.  In OG,  smoking,  lower  levels  of EPA/AA,  lessoronary  angiography
cute  coronary syndrome
aspirin  and  CCB  use were  the  risk  factors.  While  lower  levels  of EPA/AA  was the  only  risk  factor  for  ACS
that  was common  to  all patients,  YG  and OG,  docosahexaenoic  acid/AA  was  not  associated  with  ACS  in
YG  and  OG.
Conclusions:  Lower  level of  EPA/AA  is  a  common  critical  risk  factor  for  ACS  in  middle-aged  older  patients
as  well  as  younger  adult  patients.  Some  of the  risk  factors  for the  onset  of  ACS  in younger  patients  were
different  from  those  in older  patients.
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Heart disease is the second leading cause of death in Japan
1]. Recent epidemiological reports have indicated that there have
een no signiﬁcant changes in the incidence of acute myocardial
nfarction (AMI) over the past decade [2,3]. Although the preva-
ence of smoking is declining, there have also been clear changes in
ietary patterns. Low-density lipoprotein cholesterol (LDL-C) lev-
ls are poorly controlled and the number of patients with diabetes
ellitus continues to increase. If the western diet continues to be
ccepted, there may  be a further increase in the incidence of MI.
∗ Corresponding authors at: Department of Cardiology, Fukuoka University School
f Medicine, 7-45-1 Nanakuma, Jonan-ku, Fukuoka 814-0180, Japan.
el.: +81 92 801 1011; fax: +81 91 865 2692.
E-mail addresses: miuras@cis.fukuoka-u.ac.jp (S. Miura),
aku-k@fukuoka-u.ac.jp (K. Saku).
914-5087/$ – see front matter © 2013 Japanese College of Cardiology. Published by Else
ttp://dx.doi.org/10.1016/j.jjcc.2013.06.016anese  College  of Cardiology.  Published  by Elsevier  Ltd.  All  rights  reserved.
Recent papers have reported that there is a close associ-
ation between polyunsaturated fatty acids (PUFAs), including
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA),
and coronary heart disease (CAD). This association is especially
observed regarding the onset of acute coronary syndrome (ACS)
[4–6]. The consumption of PUFAs, which are essentially fatty acids,
is strongly dependent on the diet. The change in diet in Japan has
led to both a poor intake of PUFAs and the overconsumption of
arachidonic acid (AA). Younger patients have different diets than
older patients. In particular, young adult patients may  consume
fewer PUFAs than older patients. Moreover, since there has been
increasing evidence that EPA and DHA have different associations
with coronary risk factors [7], EPA and DHA may  have different
associations with ACS.
We  tested the hypothesis that coronary risk factors for the
onset of ACS, including the levels of PUFAs, in young patients are
different from those in older patients. Therefore, the aim of this
vier Ltd. All rights reserved.
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Tables 2–4 show the results of a univariate analysis for the onset
of ACS in all patients, YG, and OG, respectively. In the univariate
analysis for ACS in all patients, age, family history, smoking, TC,
Table 1
Patient characteristics in all patients, YG and OG.
All patients YG (<50 y) OG (50 y) p values
YG vs. OG
Numbers (N) 578 47 531
Age 67 ± 11 44 ± 6 70 ± 9 <0.0001
Male, N (%) 448 (78) 46 (98) 402 (76) <0.0005
ACS (%) 166 (28) 21 (45) 145 (27) 0.03
Coronary risk factors, N (%)
Diabetes mellitus 265 (46) 13 (28) 252 (48) 0.009
Family history 13 (2) 4 (9) 9 (2) 0.003
Hemodialysis 18 (3) 2 (4) 16 (3) 0.638
Dyslipidemia 314 (54) 29 (62) 285 (54) 0.289
Hypertension 365 (63) 22 (47) 343 (65) 0.015
Obesity 58 (10) 7 (15) 51 (10) 0.247
Smoking 83 (14) 12 (26) 71 (13) 0.023
Serum proﬁle
HbA1c (%) 6.3 ± 1.3 6.1 ± 2.0 6.3 ± 1.3 0.43
TC (mg/dl) 175 ± 38 201 ± 55 174 ± 35 <0.0001
TG (mg/dl) 141 ± 88 196 ± 119 135 ± 83 <0.0001
HDL-C (mg/dl) 50 ± 14 47 ± 12 51 ± 14 0.07
LDL-C (mg/dl) 97 ± 32 114 ± 45 97 ± 31 0.0008
Polyunsaturated fatty acids
EPA (g/dl) 67 ± 40 43 ± 31 67 ± 37 <0.0001
AA (g/dl) 164 ± 43 183 ± 43 163 ± 42 0.0003
DHA (g/dl) 140 ± 58 107 ± 41 145 ± 59 <0.0001
EPA + DHA (g/dl) 205 ± 88 149 ± 70 210 ± 87 <0.0001
EPA/AA 0.44 ± 0.31 0.23 ± 0.04 0.43 ± 0.01 <0.0001
DHA/AA 0.87 ± 0.36 0.59 ± 0.05 0.91 ± 0.36 <0.0001
(EPA + DHA)/AA 1.28 ± 0.55 0.83 ± 0.40 1.33 ± 0.54 <0.0001
Medications, N (%)
ARB/ACE-I  343 (59) 21 (45) 322 (61) 0.033
Asprin 457 (78) 25 (53) 432 (81) <0.0001
Thienopyridine 402 (70) 22 (47) 437 (72) 0.0004
Statin 388 (67) 28 (60) 360 (68) 0.25
OHA 159 (28) 3 (7) 156 (30) 0.007
-Blocker 180 (31) 12 (26) 168 (32) 0.386
CCB 206 (36) 12 (26) 194 (37) 0.131
Insulin 32 (6) 0 (0) 32 (6) 0.083
YG, a younger adult group; OG, a middle-aged older group; ACS, acute coronary
syndrome;  HbA1c, hemoglobin A1c; TC, total cholesterol; TG, triglyceride; HDL-C,6 T. Serikawa et al. / Journa
tudy was to clarify the differences in coronary risk factors for ACS,
nd particularly PUFAs including EPA and DHA, between younger
dult patients and middle-aged older patients.
ethods
tudy population
From January 2009 to April 2011, we enrolled 578 consecutive
atients who underwent coronary angiography (CAG) at Fukuoka
aiseikai Hospital. We  excluded patients who received EPA or in
hom the levels of serum PUFAs were not examined. We  divided
he patients into a younger adult group (YG) (<50 years, n = 47) and
 middle-aged older group (OG) (≥50 years, n = 531). Our protocol
as approved by the ethics committee of Fukuoka Saiseikai Hos-
ital. We  retrospectively collected and analyzed all data using the
atabase of Fukuoka Saiseikai Hospital.
valuation of coronary risk factors
We compared YG and OG with regard to coronary risk fac-
ors, including PUFAs. We  checked fasting serum samples, and
echecked them within 24 hours if the patient was not in a fas-
ing state. We  determined serum parameters including hemoglobin
1c (HbA1c), serum total cholesterol (TC), high-density lipoprotein
holesterol (HDL-C), LDL-C, triglycerides (TG), and PUFAs. PUFAs
EPA, AA, and DHA] were measured by an outside laboratory (SRL,
okyo, Japan) using gas chromatography (GC-2010; Shimadzu,
yoto, Japan) and a capillary column (BPX 90; Wako, Osaka, Japan).
e calculated the ratios of EPA and DHA to AA (EPA/AA and
HA/AA) and the ratios of EPA + DHA and AA [(EPA + DHA)/AA].
ther coronary risk factors included age, gender, family history,
moking, diabetes mellitus, hypertension, dyslipidemia, hemodial-
sis, and obesity. Patients who had a current systolic blood
ressure (BP)/diastolic BP (SBP/DBP) ≥ 140/90 mmHg  or who were
eceiving antihypertensive therapy were considered to have hyper-
ension. Diabetes mellitus was deﬁned using the Japan Diabetes
ociety criteria [8] or if the patient was being treated with an
ral hypoglycemic agent (OHA) or insulin. Patients with LDL-
 ≥ 140 mg/dl, TG ≥ 150 mg/dl, and/or HDL-C < 40 mg/dl, or who
ere receiving lipid-lowering therapy, were considered to have
yslipidemia. Obesity was deﬁned as a body mass index > 25 kg/m2.
edications included angiotensin-converting enzyme inhibitor
ACE-I)/angiotensin II receptor blocker (ARB), aspirin, thienopyri-
ine, statin, -blocker, calcium channel blocker (CCB), OHA, and
nsulin. Medications were checked at the time of coronary angiog-
aphy. Thienopyridines included ticlopidine and clopidogrel. OHA
ncluded sulfonylurea, metformin, -glucosidase inhibitors, and
ipeptidyl-peptidase IV inhibitors.
iagnosis of ACS
ACS  included AMI, as deﬁned by The Joint European Society
f Cardiology/American College of Cardiology Committee [9], and
nstable angina, as deﬁned according to the Braunwald classiﬁca-
ion [10].
tatistical analysis
Statistical analysis was performed using JMP  version 10.0.0 (SAS
nstitute, Cary, NC, USA). Data are expressed as the mean ± standard
eviation (SD). Categorical and continuous variables were com-
ared between groups by a chi-square analysis and Student’s
npaired t-test, respectively. Odds ratios (ORs) for the onset of
CS with 95% conﬁdence intervals (95% CI) in all patients, YG, andrdiology 63 (2014) 35–40
OG  were analyzed by a univariate analysis. A multivariate analy-
sis was  performed in all patients, YG, and OG using factors that
were deemed to be signiﬁcant by the univariate analysis. A value
of p < 0.05 was considered signiﬁcant.
Results
Patient  characteristics
Table  1 shows the characteristics in all of the patients, YG, and
OG. There are many signiﬁcant differences between YG and OG,
including age, gender, family history, diabetes mellitus, hyperten-
sion, and smoking. The percentage (%) of ACS in YG was signiﬁcantly
higher than that in OG. The levels of TC, TG, and LDL-C in YG were
signiﬁcantly higher than those in OG. Moreover, the levels of EPA,
DHA, EPA + DHA, EPA/AA, DHA/AA, and (EPA + DHA)/AA in YG were
signiﬁcantly lower than those in OG. With regard to the use of med-
ications, %ARB/ACE-I, aspirin, thienopyridine, and OHA in YG were
signiﬁcantly lower than those in OG.
Univariate analyses for ACS in all patients, OG, and YGhigh-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol;
EPA, eicosapentaenoic acid; AA, arachidonic acid; DHA, docosahexaenoic acid; ARB,
angiotensin II receptor blocker; ACE-I, angiotensin converting enzyme inhibitor;
OHA,  oral hypoglycemic agent; CCB, calcium channel blocker. Parentheses indicate
percentage (%).
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Table  2
Patient characteristics in ACS and non-ACS groups and univariate analysis for onset of ACS in all patients.
ACS (n = 166) Non-ACS (n = 412) Univariate analysis for onset of ACS
ORs 95% CI p value
Age 68 ± 10 65 ± 13 0.976 0.96–0.99 0.003
Male  (68) (78) 0.88 0.58–1.36  0.559
Coronary  risk factors
Diabetes  mellitus (40) (48) 0.731 0.51–1.05 0.092
Family  History (5) (1) 4.121 1.35–13.81 0.013
Hemodialysis (4) (3) 1.25 0.43–3.28 0.665
Dyslipidemia (57) (53) 1.179 0.82–1.70 0.373
Hypertension (63) (63) 1.006 0.69–1.47 0.974
Obesity  (14) (4) 1.732 1.98–3.02 0.059
Smoking  (21) (12) 1.908 1.17–3.08 0.009
Serum  proﬁle
HbA1c 6.2 ± 0.1 6.3 ± 0.1 0.992 0.86–1.13 0.911
TC  181 ± 3 174 ± 2 1.004 1.00–1.01 0.04
TG  135 ± 7 142 ± 4 0.999 0.99–1.00 0.374
HDL-C  48 ± 1 52 ± 1 0.978 0.96–0.99 0.002
LDL-C  105 ± 3 95 ± 2 1.009 1.00–1.02 0.001
Polyunsaturated fatty acids
EPA 58 ± 3 68 ± 2 0.993 0.98–0.99 0.004
AA  159 ± 3 166 ± 2 0.995 0.99–1.00 0.064
DHA  136 ± 5 145 ± 3 0.997 0.99–1.00 0.089
EPA  + DHA 192 ± 7 211 ± 4 0.997 0.995–1.00 0.097
EPA/AA  0.37 ± 0.02 0.44  ± 0.01 0.25  0.11–0.56 0.0005
DHA/AA  0.86 ± 0.03 0.89 ± 0.02 0.755 0.44–1.27 0.293
(EPA  + DHA)/AA 1.21 ± 0.04 1.31 ± 0.03 0.688 0.47–0.98 0.038
Medications
ARB/ACE-I  (51) (63) 0.605 0.42–0.87 0.007
Asprin  (68) (84) 0.368 0.24–0.56 <0.0001
Thienopyridine (57) (75) 0.458 0.31–0.67 <0.0001
Statin  (60) (70) 0.629 0.43–0.92 0.016
OHA  (18) (31) 0.484 0.31–0.75 0.0009
-Blocker  (26) (33) 0.701 0.47–1.04 0.081
CCB  (23) (41) 0.431 0.28–0.65 <0.0001
Insulin  (5) (6) 0.819 0.34–1.79 0.628
ORs, odds ratios; CI, conﬁdence intervals. Other abbreviations and all units as in Table 1. Parentheses indicate percentage (%).
Table 3
Patient characteristics in ACS and non-ACS groups and univariate analysis for onset of ACS in YG.
ACS (n = 21) Non-ACS (n = 26) Univariate analysis for onset of ACS
ORs 95% CI p value
Age 43 ± 1 45 ± 1 0.968 0.87–1.06 0.479
Male  (95) (100) 1.91E−07 −4.65 0.2
Coronary  risk factors
Diabetes  mellitus (14) (39) 0.731 0.05–1.05 0.059
Family  history (19) (0) 16,647,620 2.30– 0.008
Hemodialysis (0) (8) 1.05E−07 N.D. 0.118
Dyslipidemia (52) (69) 0.489 0.14–1.60 0.237
Hypertension (38) (54) 0.527 0.16–1.68 0.281
Obesity  (14) (15) 0.917 0.16–4.68 0.916
Smoking  (24) (27) 0.848 0.21–3.17 0.807
Serum  proﬁle
HbA1c 5.7 ± 0.5 6.4 ± 0.4 0.793 0.47–1.11 0.196
TC  206 ± 12 197 ± 11 1.003 0.99–1.01 0.58
TG  206 ± 27 188 ± 24 1.001 0.99–1.01 0.608
HDL-C  45 ± 3 49 ± 2 0.971 0.92–1.02 0.273
LDL-C  111 ± 11 117 ± 10 0.997 0.98–1.01 0.673
Polyunsaturated fatty acids
EPA 35 ± 7 49 ± 6 0.982 0.96–1.00 0.083
AA  176 ± 10 188 ± 9 0.993 0.98–1.01 0.319
DHA  100 ± 9 112 ± 8 0.993 0.98–1.01 0.335
EPA  + DHA 135 ± 15 161 ± 14 0.993 0.98–1.00 0.182
EPA/AA  0.19 ± 0.04 0.27 ± 0.03 0.293 0.13–0.64 0.002
DHA/AA  0.57 ± 0.05 0.61 ± 0.05 0.395 0.02–5.11 0.482
(EPA  + DHA)/AA 0.75 ± 0.09 0.89 ± 0.08 0.384 0.06–1.85 0.244
Medications
ARB/ACE-I  (19) (65) 0.124 0.03–0.45 0.001
Asprin  (38) (65) 0.325 0.95–10.6 0.060
Thienopyridine (38) (54) 0.527 0.16–1.68 0.280
Statin  (48) (69) 0.404 0.12–1.31 0.132
OHA  (0) (12) 8.89E−09 N.D. 0.053
-Blocker  (19) (31) 0.529 0.12–2.01 0.355
CCB  (14) (35) 0.314 0.06–1.26 0.104
Insulin  (0) (0) N.D. N.D. N.D.
ORs, odds ratios; CI, conﬁdence intervals; N.D., not determined. Other abbreviations and all units as in Table 1. Parentheses indicate percentage (%).
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Table  4
Patient characteristics in ACS and non-ACS groups and univariate analysis for onset of ACS in OG.
ACS (n = 145) Non-ACS (n = 386) Univariate analysis for onset of ACS
ORs 95% CI p value
Age 68 ± 0.8 70 ± 0.5 0.981 0.96–1.00 0.08
Male  (73) (77) 0.826 0.54–1.29 0.39
Coronary  risk factors
Diabetes  mellitus (44) (49) 0.832 0.57–1.22 0.347
Family history (3) (1) 0.267 0.53–8.28 0.267
Hemodialysis (4) (3) 1.623 0.54–4.45 0.368
Dyslipidemia (58) (52) 1.267 0.86–1.87 0.237
Hypertension (67) (64) 1.15 0.77–1.73 0.495
Obesity  (14) (8) 1.832 1.99–3.31 0.052
Smoking  (20) (11) 2.048 1.21–3.43 0.008
Serum proﬁle
HbA1c 6.3 ± 0.1 6.2 ± 0.1 1.045 0.90–1.21 0.57
TC  177 ± 2.9 172 ± 1.8 1.004 0.99–1.01 0.13
TG  125 ± 7.0 139 ± 4.3 1.001 0.99–1.00 0.07
HDL-C  48 ± 1.1 52 ± 0.7 0.979 0.96–0.99 0.273
LDL-C  104 ± 2.6 94 ± 1.6 1.011 1.00–1.02 0.673
Polyunsaturated fatty acids
EPA 62 ± 3 69 ± 2 0.994 0.98–0.99 0.038
AA  157 ± 4 165 ± 2 0.995 0.990–0.999 0.045
DHA  141 ± 5 147 ± 3 0.377 0.06–2.17 0.28
EPA  + DHA 200 ± 7 214 ± 4 1.001 0.99–1.00 0.119
EPA/AA  0.40 ± 0.02 0.46 ± 0.01 0.392 0.17–0.86 0.019
DHA/AA  0.90 ± 0.03 0.91 ± 0.02 0.919 0.52–1.57 0.763
(EPA  + DHA)/AA 1.28 ± 0.05 1.34 ± 0.03 1.226 0.85–1.80 0.279
Medications
ARB/ACE-I  (55) (63) 0.732 0.50–1.08 0.115
Asprin  (70) (86) 0.403 0.26–0.64 0.0001
Thienopyridine (60) (76) 0.476 0.32–0.72 0.0004
Statin  (61) (70) 0.674 0.45–1.00 0.054
OHA  (21) (33) 0.538 0.34–0.84 0.006
-Blocker  (27) (33) 0.732 0.48–1.11 0.146
CCB  (24) (41) 0.454 0.29–0.69 0.0002
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Rs, odds ratios; CI, conﬁdence intervals. Other abbreviations and all units as in Tab
DL-C, LDL-C, EPA, EPA/AA, (EPA + DHA)/AA, ARB/ACE-I, aspirin,
hienopyridine, statin, OHA, and CCB were signiﬁcantly associated
ith the onset of ACS (Table 2). In YG, a univariate analysis revealed
hat family history, EPA/AA, and ARB/ACE-I were associated with
CS (Table 3). As shown in Table 4, smoking, EPA, AA, EPA/AA,
spirin, thienopyridine, OHA, and CCB were signiﬁcantly associated
ith ACS in OG.
ultivariate analyses for ACS in all patients, OG, and YG
Since  EPA/AA is signiﬁcantly associated with EPA (r = 0.862,
 < 0.0001) and (EPA + DHA)/AA (r = 0.779, p < 0.0001), and since
PA/AA (p = 0.0005) showed the highest signiﬁcant association for
he onset of ACS among the 3 factors as assessed by the uni-
ariate analysis (Table 2), a multivariate analysis was  performed
n all patients using the signiﬁcant factors (age, family history,
moking, TC, HDL-C, LDL-C, EPA/AA, ARB/ACE-I, aspirin, thienopy-
idine, statin, OHA, and CCB) except for EPA and (EPA + DHA)/AA.
ower levels of HDL-C (p = 0.005) and EPA/AA (p = 0.023), less use of
spirin (p = 0.037), OHA (p = 0.014), and CCB (p = 0.001) were shown
o be independent risk factors for ACS (Fig. 1A). In YG, EPA/AA
p = 0.002) showed only signiﬁcant association for the onset of ACS
mong PUFAs as assessed by the univariate analysis (Table 3).
he multivariate analysis indicated that lower levels of EPA/AA
p = 0.03) and less administration of ARB/ACE-I (p = 0.01) were the
nly independent risk factors for ACS (Fig. 1B). In OG, since EPA/AA
s signiﬁcantly associated with EPA (r = 0.901, p < 0.0001) and AA
r = −0.215, p < 0.0001), and since EPA/AA (p = 0.0019) showed the
ighest signiﬁcant association for the onset of ACS among the 3
actors as assessed by the univariate analysis (Table 4), a multi-
ariate analysis was performed in OG using the signiﬁcant factors0.881 0.36–1.93 0.761
arentheses indicate percentage (%).
(smoking,  EPA/AA, aspirin, thienopyridine, OHA, and CCB) except
for EPA and AA. Smoking (p = 0.013), lower levels of EPA/AA
(p = 0.03), less use of aspirin (p = 0.04) and CCB (p = 0.001) were the
independent risk factors for ACS in OG (Fig. 1C). Thus, lower level
of EPA/AA was  the only common risk factor for ACS in all patients,
YG, and OG.
Discussion
First,  our data indicated that lower level of EPA/AA, but not
DHA/AA, is a common critical risk factor for ACS in both middle-
aged older patients and younger adult patients, although coronary
risk factors for the onset of ACS in younger adult patients may  be
different from those in older patients. Second, lower level of HDL-C,
less aspirin, OHA, and CCB use in addition to EPA/AA were indepen-
dent risk factors for ACS in all patients. Finally, some risk factors for
the onset of ACS in young patients were different from those in
older patients. Less ARB/ACE-I use was an independent risk factor
in YG, whereas smoking, less aspirin and CCB use were risk factors
in OG.
We  made an interesting ﬁnding regarding PUFAs as an indepen-
dent risk factor for ACS; speciﬁcally, EPA/AA, but not DHA/AA, was
an independent risk factor in both YG and OG. Several reports have
indicated that the intake of omega-3 fatty acids reduces the inci-
dence of CAD [11–14]. CAD has been shown to be caused by lower
levels of EPA/AA [15]. Recently, Lee et al. reported that plasma EPA
level, but not plasma DHA level, is a predictor of major adverse car-
diac events (MACE) in patients with AMI  [16], and the incidence
of MACE in patients who  have undergone percutaneous coronary
intervention is signiﬁcantly associated with serum EPA/AA ratio
[17]. In addition, decreases in serum EPA/AA are associated with
T. Serikawa et al. / Journal of Car
Age
Family history
Smoking
TC
HDL-C
LDL-C
EPA/AA
ARB/ACE-I
Aspirin
Tienopiridine
Statin
OHA
CCB
1.01 (0.99-1.03)
1.33 (0.34-5.43)
1.57 (0.89-2.75)
1.00 (0.99-1.01)
0.98 (0.96-0.99)
1.00 (0.98-1.01)
0.37 (0.14-0.87)
0.96 (0.62-1.51)
0.53 (0.29-0.96)
0.64 (0.38-1.09)
1.08 (0.65-1.80)
0.55 (0.33-0.89)
0.49 (0.30-0.76)
ORs (95% C.I.)
0.1                 1                 10
ORs (95% C.I.)
A.
B.
Smoking
EPA/AA
Aspirin
Tienopiridine
OHA
CCB
2.03 (1.16-3.49)
0.40 (0.17-0.90)
0.54 (0.30-0.97)
0.63 (0.38-1.07)
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Fig. 1. Odds ratios (ORs) [95% conﬁdence intervals (CIs)] in all patients (A), a younger
adult group (B) and a middle-aged older group (C). TC, total cholesterol; HDL-C,
high-density  lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol;
EPA, eicosapentaenoic acid; AA, arachidonic acid; ARB, angiotensin receptor blocker;
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[3] Maruyama M,  Ohira T, Imano H, Kitamura A, Kiyama M,  Okada T, Maeda K,
Yamagishi  K, Noda H, Ishikawa Y, Shimamoto T, Iso H. Trends in sudden cardiacCE-I, angiotensin-converting enzyme inhibitor; OHA, oral hypoglycemic agent;
CB, calcium channel blocker.
rogression in coronary atherosclerosis [18]. Although omega-3-
cid ethyl esters (EPA + DHA) have been shown to reduce TG and
ncrease HDL-C [19] and to have pleiotropic effects [20], there are
ifferences in the pharmacological effects of EPA and DHA [21,22].
PA is converted to 5-series leukotriene, 3-series prostaglandin,
nd thromboxanes, which are overall less inﬂammatory than the
A-derived eicosanoids [7]. In contrast to DHA, EPA is a direct sub-
trate of cyclooxygenase for the synthesis of anti-inﬂammatory and
nti-aggregatory mediators. Thus, EPA has an anti-atherosclerotic
ffect and reduces platelet aggregation [23,24] in addition to an
nti-arrythmogenic effect [25,26]. EPA administration has been
hown to reduce the incidence of major coronary events by 19%
n Japan [15]. On the other hand, DHA elevates the levels of HDL-C
nd LDL-C and increases HDL and LDL particle size [7,27–29]. More-
ver, Itakura et al. reported that the changes in DHA, but not in EPA,
ere positively correlated with the changes in LDL-C [30], although
HA mildly reduced both the heart rate at rest and blood pressure
27]. Thus, EPA and DHA may  have different effects with regard to
he onset of ACS. In fact, Lee et al. reported that the plasma level of
PA, but not DHA, was a predictor of major cardiovascular events
n patients with AMI [31].
We  found that lower levels of HDL-C, less aspirin, OHA, and CCB
se in addition to lower levels of EPA/AA were independent risk fac-
ors for ACS in all patients. It is well known that a lower plasma level
f HDL-C is an independent coronary risk factor [32,33]. Althoughdiology 63 (2014) 35–40 39
the  rate of statin use in this study was relatively high (67%), Jafri
et al. reported that a lower HDL-C level during statin treatment was
also a coronary risk factor [34]. Aspirin for the primary prevention
of CAD has been shown to reduce the risk of MI [35,36]. Diabetes
mellitus is a coronary risk factor and treatment with OHA is useful
for preventing CAD [37,38], although it is unclear whether the use
of intensive therapy to target normal glycated hemoglobin levels
is useful compared to standard therapy for signiﬁcantly reducing
major cardiovascular events [39]. Since ACS is caused by coronary
artery spasm [40,41], and since coronary spasm can be controlled by
CCB, the lower use of CCB may  also be a factor in all patients. Thus,
the administration of aspirin, OHA, or CCB may  be also presumed
to be helpful for preventing ACS in the present study.
Our data showed that the independent factors were different
for YG and OG. Less aspirin and CCB use were independent factors
in OG, but not YG. Since older patients generally show accelerated
platelet aggregation activity [42–44], less aspirin use may  only be a
factor in OG. In YG, the lower use of ARB or ACE-I use was shown to
be an independent risk factor. ACE-I have been shown to be effec-
tive for the primary prevention of MI  [45–47]. The ONTARGET trial
reported that the effect of ARB was  equivalent to that of ACE-I for
preventing cardiovascular events [48]. In our study, ARB or ACE-I
use in YG was  lower than that in OG. Furthermore, the incidence of
ACS in YG was signiﬁcantly higher than that in OG. Our results sug-
gest that the greater use of ARB or ACE-I in YG may have suppressed
the onset of ACS. Smoking is a risk factor for AMI  [49,50]. Although
the rate of smoking in YG was  greater than that in OG, the overall
duration of smoking was relatively short. Thus, smoking may  not
be an independent risk factor in YG.
This study has several limitations. First, this study was
cross-sectional. Second, CAG was  performed after various treat-
ments. Many of the patients were taking anti-hypertensive,
anti-dyslipidemic, and/or anti-diabetic medications that might
inﬂuence the onset of ACS. Understandably, the middle-aged older
patients were taking more medications than the younger adult
patients and we performed a multivariate analysis for ACS. Prospec-
tive studies are needed to clarify the effects of these limitations.
Conclusions
Lower  level of EPA/AA, but not DHA/AA, was  a common critical
risk factor for ACS in both middle-aged older patients and younger
adult patients. Lower level of HDL-C, less aspirin, OHA, and CCB
use were also independent risk factors in all patients. However,
some risk factors for the onset of ACS in younger patients were
different from those in older patients. We  need to manage patients
aggressively for the primary prevention of ACS according to the risk
factors.
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